- Home
- NRIX vs ASGI Comparison
NRIX vs ASGI Comparison
Compare NRIX & ASGI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRIX
- ASGI
- Stock Information
- Founded
- NRIX 2009
- ASGI 2019
- Country
- NRIX United States
- ASGI United States
- Employees
- NRIX N/A
- ASGI N/A
- Industry
- NRIX Biotechnology: Pharmaceutical Preparations
- ASGI Investment Managers
- Sector
- NRIX Health Care
- ASGI Finance
- Exchange
- NRIX Nasdaq
- ASGI Nasdaq
- Market Cap
- NRIX 728.6M
- ASGI 610.7M
- IPO Year
- NRIX 2020
- ASGI N/A
- Fundamental
- Price
- NRIX $8.97
- ASGI $20.98
- Analyst Decision
- NRIX Strong Buy
- ASGI
- Analyst Count
- NRIX 14
- ASGI 0
- Target Price
- NRIX $29.07
- ASGI N/A
- AVG Volume (30 Days)
- NRIX 847.4K
- ASGI 83.3K
- Earning Date
- NRIX 10-10-2025
- ASGI 01-01-0001
- Dividend Yield
- NRIX N/A
- ASGI 8.76%
- EPS Growth
- NRIX N/A
- ASGI N/A
- EPS
- NRIX N/A
- ASGI N/A
- Revenue
- NRIX $88,381,000.00
- ASGI N/A
- Revenue This Year
- NRIX $74.59
- ASGI N/A
- Revenue Next Year
- NRIX N/A
- ASGI N/A
- P/E Ratio
- NRIX N/A
- ASGI N/A
- Revenue Growth
- NRIX 41.86
- ASGI N/A
- 52 Week Low
- NRIX $8.18
- ASGI $14.96
- 52 Week High
- NRIX $29.56
- ASGI $18.55
- Technical
- Relative Strength Index (RSI)
- NRIX 42.73
- ASGI 55.01
- Support Level
- NRIX $8.33
- ASGI $20.92
- Resistance Level
- NRIX $10.13
- ASGI $21.24
- Average True Range (ATR)
- NRIX 0.49
- ASGI 0.22
- MACD
- NRIX -0.00
- ASGI 0.07
- Stochastic Oscillator
- NRIX 35.56
- ASGI 78.46
About NRIX Nurix Therapeutics Inc. Common stock
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.
About ASGI abrdn Global Infrastructure Income Fund of Beneficial Interest
abrdn Global Infrastructure Income Fund is a non-diversified, closed-end management investment company. Its objective is to seek to provide a high level of total return with an emphasis on current income by investing in assets that provide necessary services to society.